Raymond James analyst John Ransom upgraded DaVita (DVA) to Outperform from Market Perform with a price target of $70. The analyst notes that the stock has fallen about 18% since the company reported a Q3 earnings miss and since the defeat of the California ballot initiative, creating an attractive entry point. Ransom also points to yesterday's constructive commentary from UnitedHealth (UNH) regarding their pending acquisition of DaVita Medical Group along with the 8-K filing by the latter stating that the bank covenant timetable for closing the deal has been extended by 6 months.
https://thefly.com/landingPageNews.php?id=2829105
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.